(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

H.F.M STEM CELLS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

H.F.M STEM CELLS

ST13

US500000079311220

Class

1, 5, 42, 44

Filing

79311220

Registration

7014490

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

41

Latest update

08/14/2023

Trademark type

Word

Nice classes

1, 5, 42, 44

Filing date

12/21/2020

Registration date

04/04/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/04/2023

Last transaction

04/04/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

01

Owner location

DE

Examiner

ROACH, APRIL

Law office

M60

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

D. G. (pessoa física)

Representatives

Sean K. Owens WOOD HERRON & EVANS LLP

Technical classification

Nice Classes

Class 1Class 5Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Stem cells for scientific or research use; cell growth media for growing cells for scientific use

Class 5

pharmaceutical drugsnamely pharmaceutical drugs for treatment of skin diseasesantibioticsimmune suppressantsanti-inflammatory pharmaceuticals; pharmaceutical drugs for treatment of disease and disorders of the respiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe nervous systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive systemfor the treatment of blood diseases and disorders; pharmaceutical and veterinary preparations for treatment of vertigomigrainenauseavomitingfor treatment of skin diseaseswound healing; pharmaceutical preparations for anti-aging; pharmaceutical preparations namely antibiotics; diagnostic agents for medical use; preparations for medical purposesfor the treatment of skin diseases; substances for medical usefor regeneration of tissue and anti-inflammation; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposesfor anti-agingfor use in dermatology procedures; somatic stem cell therapeuticsfor medical therapeutic use; fibroblasts for medical use; fibroblasts for aesthetic purposesfor use in dermatology procedures; pharmaceutical implantsimplantable subcutaneous drug delivery devices sold filled with pharmaceutical for treatment of skin diseasesblood diseasesvertigonauseavomitingmigrainerespiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive system; surgical implants derived from stem cellssurgical implants derived from living tissues and living stem cells; surgical implants derived from fibroblastssurgical implants comprised of living fibroblasts tissue cells; biological tissue for implantationimplants comprising living tissues; cell growth media for growing cells for medical use; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissuesurgical implants comprised of living tissues; biotechnologically engineered tissue productsliving tissue cell sheets and plasters for wound healing and burnsbiological eye lens graftsbone grafts in the nature of biological bone tissue for graftingbiological tissue graftshuman allograft tissue

Class 42

Stem cell research; scientific research and development and medical research and development in the field of stem cellsvaccines and medications; scientific researchtesting and analysis services in the field of regenerative medicine and tissue engineeringgenetics and genetic engineering; scientific research for medical purposes; medical research; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information on medical and scientific research on pharmaceutical products; biomedical research; preparation of reports relating to scientific researchtechnical writing for others; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology; development of industrial processesengineering of industrial processes in the field of for packagingstorage and transport of human tissue and human adult ancestral cellsengineering of industrial processes to manufacture stem cells; industrial process research in the field of regenerative medicine and tissue engineeringchemical engineering

Class 44

Medical services relating to the removaltreatmentprocessing and preservation of human cells and tissuestem cells and bone marrowalso in the field of regenerative medicineincluding tissue engineering; medical services in connection with the removaltreatment and processing of human tissue and stem cellshuman tissue and stem cell bank servicesincluding in the field of regenerative medicineincluding tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells

Publications

History of USPTO decisions and trademark events.

41 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

08/14/2023

FICS

FINAL DISPOSITION NOTICE SENT TO IB

07/20/2023

FIMP

FINAL DISPOSITION PROCESSED

07/20/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

07/04/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

04/04/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

04/04/2023

GPNX

NOTIFICATION PROCESSED BY IB

01/24/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

01/17/2023

PUBO

PUBLISHED FOR OPPOSITION

01/17/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

01/04/2023

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

01/04/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

12/28/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/15/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

12/15/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

12/15/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

12/15/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

12/15/2022

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

11/13/2022

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

10/26/2022

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

10/26/2022

RDX3

NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED

06/15/2022

RDX1

ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED

06/15/2022

RRDX

ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED

06/15/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/09/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/08/2022

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

06/08/2022

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

12/22/2021

GNFR

FINAL REFUSAL E-MAILED

12/22/2021

CNFR

FINAL REFUSAL WRITTEN

12/22/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/21/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/20/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/20/2021

RFNT

REFUSAL PROCESSED BY IB

07/19/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

06/26/2021

RFRR

REFUSAL PROCESSED BY MPU

06/25/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

06/18/2021

CNRT

NON-FINAL ACTION WRITTEN

06/17/2021

DOCK

ASSIGNED TO EXAMINER

06/16/2021

MAFR

APPLICATION FILING RECEIPT MAILED

05/25/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/21/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

05/20/2021

Continuous trademark protection

Get notified about every new filing that threatens H.F.M STEM CELLS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.